Curia, a New York-based CDMO, inked a deal with the U.S. government to provide domestic production of injectable medicines and expand its manufacturing operations in New Mexico.
The agreement allows Curia to add a new high-speed fill-finish line at its Albuquerque, New Mexico, production facility as part of a 65,000-square-foot expansion that will include a pair of 430-square-foot lyophilizers, automated visual inspection technology, automated packaging capacity, ultra-cold storage capability and other enhanced security features. The company also said it is adding an isolated flexible filling line to a nearby filling facility in Albuquerque.
“This agreement not only secures our continued contribution to the nation’s pandemic response plans, it also enables us to meet the need to deliver life-changing life science to patients into the future,” John Ratliff, Curia’s chairman and chief executive, said in a statement.
Curia didn't disclose the amount of funding it's set to net from the Biomedical Advanced Research and Development Authority and other government agencies.
Curia, formerly known as Albany Molecular Research (AMRI), recently announced that two of its recent acquisitions—Integrity Bio and LakePharma—have been fully integrated under the Curia umbrella. Both Integrity Bio, a formulation and fill-finish specialist and LakePharma, a biologics R&D and manufacturer, were purchased for undisclosed amounts in July.
For its part, Curia was snapped up by private equity investors The Carlyle Group and GTCR for $920 million in 2017.